July 19th 2024
The study has enrolled 8 patients to assess the safety and efficacy of the device in sealed vasectomy procedures.
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Basic Science Research: Trimodal therapy shows promise in oligometastatic PCa
July 1st 2016Other basic science research pearls include preliminary evidence from a porcine model suggesting botulinum toxin type A facilitates ureteral stone passage and the identification of two different microdeletions in the NELL1 gene on chromosome 11 in men with Peyronie's disease.
Penile, Testis, and Urethral Ca: Robotic RPLND found safe
July 1st 2016Research on the use of a CO2 laser for penile carcinoma in situ and FDG positron positron emission tomography-computed tomography in identifying inguinal nodal metastasis (with clinically node negative groins) during monitoring after primary treatment for penile squamous cell carcinoma were among key abstracts in the area of penile, testis, and urethral cancer.
Outcomes Analysis: Decline observed in PSA-based screening for PCa
July 1st 2016Studies about ProPublica's Surgeon Scorecard, urology participation in accountable care organizations, and Twitter were among the take-home messages in outcomes analysis at the 2016 AUA annual meeting. The take-homes were presented by Christopher Saigal, MD, MPH, of the University of California, Los Angeles.
Low concordance with NCCN surveillance guide seen
July 1st 2016Concordance with National Cancer Comprehensive Network recommendations about follow-up during active surveillance for low-risk prostate cancer is generally low across urology practices in Michigan, reported researchers from the Michigan Urological Surgery Improvement Collaborative at the AUA annual meeting in San Diego.
Adjuvant chemo well tolerated in high-risk PCa patients
July 1st 2016A Veterans Administration Cooperative Study investigating chemotherapy after prostatectomy for high-risk prostate cancer was underpowered to show a statistically significant benefit of early adjuvant chemotherapy versus observation as the standard of care in the primary endpoint analysis of progression-free survival.
The Affordable Care Act: How it has impacted men’s health
May 12th 2016The ACA is a large step forward in allowing men to embrace their health concerns, and for health care practitioners to understand men and the challenge of help seeking, masculinity, and disparity in their quest for wellness (Men’s Health in Primary Care [Current Clinical Practice]. Switzerland: Springer International Publishing, 2016).
Greater long-term side effect risk with intermittent ADT
May 1st 2016In men with metastatic prostate cancer, those assigned to intermittent androgen deprivation therapy have more ischemic and thrombotic events than those assigned to continuous androgen deprivation, according to Columbia University researchers.